Life sciences company VolitionRx Ltd. closed an underwritten public offering of 3.5 million common shares at $2.40 apiece to raise gross proceeds of about $8.4 million.
The net proceeds will be used for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes.
Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering, while National Securities Corp. acted as a co-manager for the offering.
